IMMIX BIOPHARMA INC.

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

11 12 2023 08:36:00 提供 Nasdaq GlobeNewswire

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

30 11 2023 08:46:00 提供 Nasdaq GlobeNewswire

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

22 11 2023 08:19:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

21 11 2023 08:46:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

21 11 2023 08:46:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

06 11 2023 08:12:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

06 11 2023 07:40:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

26 10 2023 07:58:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

16 10 2023 08:05:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

03 10 2023 08:14:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

02 10 2023 07:06:00 提供 Nasdaq GlobeNewswire

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis

21 9 2023 07:55:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

19 9 2023 08:10:00 提供 Nasdaq GlobeNewswire

Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

07 9 2023 07:41:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

01 9 2023 07:39:00 提供 Nasdaq GlobeNewswire

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

23 8 2023 07:37:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

18 8 2023 08:20:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)

16 8 2023 08:05:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting

25 7 2023 07:42:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial

17 7 2023 08:37:00 提供 Nasdaq GlobeNewswire